Table 1.
Main characteristics of included studies
| Study | Country | Participants | Intervention | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Group | Male/Female | Age (years) | N | TMD diagnosis | Type | Centrifugal method | Centrifugal speed/time | |||
| HA:PO | 1 Gorrela, H/2017 | India | HA | 34/28 | no report | 62 | ID | arthrocentesis + intra-articular injection 1 ml HA | — | — |
| placebo | arthrocentesis | — | — | |||||||
| 2 Patel, P/2016 | India | placebo | 9/21 | no report | 30 | ID | arthrocentesis | — | — | |
| HA | arthrocentesis + intra-articular injection 1 ml HA | — | — | |||||||
| 3 Rao, J. K. D/2019 | India | placebo | 7/3 | 37 ± 16.11 | 20 | ID | arthrocentesis | — | — | |
| HA group | 7/3 | 34.2 ± 12.54 | arthrocentesis + intra-articular injection 1 ml HA | — | — | |||||
| 4 Yapıcı-Yavuz, G/2018 | Turkey | group 1 | 6/38 | no report | 44 | DDwoR | arthrocentesis | — | — | |
| group 2 | arthrocentesis + intra-articular injection HA | — | — | |||||||
| group 3 | arthrocentesis + intra-articular injection methylprednisolone acetate | — | — | |||||||
| group 4 | arthrocentesis + intra-articular injection tenoxicam | — | — | |||||||
| PRP:PO | 5 Chandra, L/2021 | India | PRP | no report | 32.3 ± 10.4 | 44 | TMD | intra-articular injection 0.6 ml PRP | double centrifugation | 1800 rpm 15 min; 3500rpm10min |
| placebo | 29.00 ± 8.3 | arthrocentesis | — | — | ||||||
| 6 Hancı, M/2015 | Turkey | PRP | no report | 27.2 ± 13.4 | 20 | DDwR | intra-articular injection 0.6 ml PRP | double centrifugation | 1000xg 20 min; 1500xg 10 min | |
| placebo | 3/7 | 25.4 ± 1.7 | arthrocentesis | — | — | |||||
| 7 Rajput, A/2020 | India | placebo | 7/5 | 22.17 ± 3.61 | 24 | TMD | arthrocentesis | — | — | |
| PRP | 2/10 | 27.83 ± 11.71 | intra-articular injection PRP | double centrifugation | 1800 rpm 15 min; 3500 rpm 10 min | |||||
| 8 Singh, A. K/2021 | India | PRP | 4/8 | 34.75 ± 10.83 | 24 | ID | arthrocentesis + intra-articular injection 1mlPRP | single-step centrifugation | 2000 rpm 8 min | |
| placebo | 2/10 | 36.41 ± 11.15 | arthrocentesis | — | — | |||||
| PRF:PO | 9 Ghoneim, N. I/2021 | Egypt | placebo | 7/13 | 28.60 ± 8.42 | 40 | ID | arthrocentesis | — | — |
| PRF | 4/16 | 26.45 ± 8.21 | arthrocentesis + intra-articular injection 1.5 ml PRF | single-step centrifugation | 700 rpm 3 min | |||||
| 10 Karadayi, U/2021 | Turkey | placebo | 9/9 | 39.67 | 36 | ID | arthrocentesis | — | — | |
| PRF | 8/10 | 39.97 | arthrocentesis + intra-articular injection 2 ml PRF | single-step centrifugation | 700 rpm 3 min | |||||
| HA:PRP:PO | 11 Jacob, S. M/2021 | India | PRP | 4/12 | 40.56 ± 9.72 | 47 | ID | arthrocentesis + intra-articular injection 1 ml PRP | single-step centrifugation | no report |
| HA | 6/9 | 46.53 ± 19.15 | arthrocentesis + intra-articular injection 1 ml HA | — | — | |||||
| placebo | 7/9 | 51.50 ± 12.80 | arthrocentesis | — | — | |||||
| 12 Toameh, M. H/2019 | Syria | placebo | 2/8 | 40.53 | 30 | DDwoR | arthrocentesis | — | — | |
| HA | 3/7 | 38.26 | arthrocentesis + intra-articular injection 1 ml HA | — | — | |||||
| PRP | 1/9 | 37.82 | arthrocentesis + intra-articular injection 1 ml PRP | single-step centrifugation | 3400 rpm 4 min | |||||
HA Hyaluronic acid, PRP Platelet-rich plasma, PRF Platelet-rich fibrin, PO Placebo, ID Internal derangements, DDwR Disc displacement with reduction, DDwoR Disc displacement without reduction, TMD Temporomandibular disorders